中文(繁體)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Journal of Biological Regulators and Homeostatic Agents

Langerhans cell sarcoma: an unusual microscopic presentation.

只有註冊用戶可以翻譯文章
登陸註冊
鏈接已保存到剪貼板
A L Gagnon
S Daniel
K Greer
J W Patterson
G Tchernev
A A Chokoeva
U Wollina
T Lotti
M Fioranelli
M G Roccia

關鍵詞

抽象

A 70-year-old Caucasian male presented to our clinic for a pruritic eruption progressing over several months. He complained of fatigue with a 20-pound weight loss over the past year. On presentation, the patient had browny-yellow to violaceous, purpuric, macular and papular lesions on the legs, arms, lower abdomen and back. Initial biopsy showed an angiocentric infiltrate with a suggestion of intraluminal proliferation; CD31 and Fli-1 positivity suggested either reactive angioendotheliomatosis or an unusual intravascular histiocytosis. Further excisional biopsies demonstrated perivascular collections of cells with ample cytoplasm, prominent nuclear pleomorphism and mitotic activity. The nuclei demonstrated nuclear folding, grooves and indentations. The atypical cells were S100, CD1a and CD56 positive with immunohistochemistry. A diagnosis of Langerhans cell sarcoma (LCS) was made. LCS is a rare, aggressive malignancy that can involve multiple organs including the skin, lymph nodes, lung, bone marrow, spleen, heart, and brain. The skin and lymph nodes are commonly involved, and the cutaneous presentation varies greatly. Immunohistochemistry characteristically shows CD1a and S100 positivity. CD56 expression is uncommon and often portends a poor prognosis. There is no established treatment of LCS due to its rarity. Surgery, radiation, and chemotherapy have been used with varied outcomes. Our patient was treated with prednisone with improvement of cutaneous disease. He did not develop systemic involvement, but died 1.5 years later from complications associated with heart failure. Langerhans cell sarcoma should be considered when faced with an unusual angiocentric infiltrate in which initial immunohistochemical staining results may be misleading.

加入我們的臉書專頁

科學支持的最完整的草藥數據庫

  • 支持55種語言
  • 科學支持的草藥療法
  • 通過圖像識別草藥
  • 交互式GPS地圖-在位置標記草藥(即將推出)
  • 閱讀與您的搜索相關的科學出版物
  • 通過藥效搜索藥草
  • 組織您的興趣並及時了解新聞研究,臨床試驗和專利

輸入症狀或疾病,並閱讀可能有用的草藥,輸入草藥並查看其所針對的疾病和症狀。
*所有信息均基於已發表的科學研究

Google Play badgeApp Store badge